<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02772497</url>
  </required_header>
  <id_info>
    <org_study_id>Protocol DME1</org_study_id>
    <nct_id>NCT02772497</nct_id>
  </id_info>
  <brief_title>3 Month Outcome of Ziv-aflibercept for DME</brief_title>
  <official_title>Three-month Outcome of Ziv-aflibercept for Diabetic Macular Edema</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Marashi Eye Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Marashi Eye Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose is to show the 3-month efficacy and safety in diabetic macular edema treated with&#xD;
      intravitreal ziv-aflibercept.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Multi-studies have shown that Intravitreal aflibercept (Eylea) is effective and safe in&#xD;
      diabetic macular edema (DME) treatment and has gained FDA approval but it is expansive where&#xD;
      ziv aflibercept (ZALTRAP) has the same molecule but with high osmilar buffer solution which&#xD;
      is FDA approved for colon rectus cancer treatment and it is cost effective.&#xD;
&#xD;
      Studies have shown that intravitreal ziv aflibercept is safe and nontoxic despite the high&#xD;
      osmolarity and even has short term effect in wet age related macular degeneration.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Actual">May 2016</completion_date>
  <primary_completion_date type="Actual">May 2016</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of visual acuity improvement using Snellen chart or equivalent</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Amount of Central macular thickness reduction in microns after ziv-aflibercept treatment</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amount of treatment cost in USD dollars</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of eyes with retinal toxicity after ziv aflibercept treatment</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Diabetic Macular Edema</condition>
  <arm_group>
    <arm_group_label>Ziv aflibercept</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravitreal ziv aflibercept 1.25 mg (0.05ml) every 4 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ziv aflibercept</intervention_name>
    <description>Intravitreal ziv aflibercept 1.25 mg (0,05ml) every 4 weeks</description>
    <arm_group_label>Ziv aflibercept</arm_group_label>
    <other_name>ZALTRAP</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with central diabetic macular edema&#xD;
&#xD;
          -  Best corrected visual acuity is 20/25 or less&#xD;
&#xD;
          -  Central macular thickness more than 250 microns&#xD;
&#xD;
          -  Patients who are able to come for all follow-up&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Significant renal disease, defined as a history of chronic renal failure requiring&#xD;
             dialysis or kidney transplant.&#xD;
&#xD;
          -  Myocardial infarction, other acute cardiac event requiring hospitalization, stroke,&#xD;
             transient ischemic attack, or treatment for acute congestive heart failure within 4&#xD;
             months prior to randomization&#xD;
&#xD;
          -  For women of child-bearing potential: pregnant or lactating or intending to become&#xD;
             pregnant within the next 3 years.&#xD;
&#xD;
          -  Macular edema is present that is considered to be related to ocular surgery such as&#xD;
             cataract extraction&#xD;
&#xD;
          -  Substantial cataract that, in the opinion of the investigator, is likely to be&#xD;
             decreasing visual acuity by 3 lines or more&#xD;
&#xD;
          -  History of major ocular surgery (including vitrectomy, scleral buckle, any intraocular&#xD;
             surgery, etc.) within prior 4 months or anticipated within the next 6 months following&#xD;
             randomization.&#xD;
&#xD;
          -  Exam evidence of severe external ocular infection, including conjunctivitis,&#xD;
             chalazion, or substantial blepharitis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ameen Marashi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Aleppo Syria</affiliation>
  </overall_official>
  <link>
    <url>http://medcraveonline.com/AOVS/AOVS-04-00114.pdf</url>
    <description>Marashi A (2016) Three-Month Outcome of Ziv-Aflibercept for Diabetic Macular Edema. Adv Ophthalmol Vis Syst 4(3): 00114. DOI: 10.15406/aovs.2016.04.00114</description>
  </link>
  <results_reference>
    <citation>Marashi A (2016) Three-Month Outcome of Ziv-Aflibercept for Diabetic Macular Edema. Adv Ophthalmol Vis Syst 4(3): 00114. DOI: 10.15406/aovs.2016.04.00114</citation>
  </results_reference>
  <verification_date>July 2017</verification_date>
  <study_first_submitted>May 11, 2016</study_first_submitted>
  <study_first_submitted_qc>May 12, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 13, 2016</study_first_posted>
  <last_update_submitted>July 3, 2017</last_update_submitted>
  <last_update_submitted_qc>July 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Marashi Eye Clinic</investigator_affiliation>
    <investigator_full_name>Ameen Marashi</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>DME</keyword>
  <keyword>Anti VEGF</keyword>
  <keyword>VEGF trap</keyword>
  <keyword>Diabetes</keyword>
  <keyword>Diabetic retinopathy</keyword>
  <keyword>ZALTRAP</keyword>
  <keyword>Ziv aflibercept</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Edema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aflibercept</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

